Monitor upcoming clinical data readouts for KT-621 in mid-2027 (atopic dermatitis) and late-2027 (asthma), and KT-579 data in 2H26. The increased R&D spend with declining collaboration revenue suggests the company is prioritizing pipeline advancement over near-term profitability.
Price Chart
Executive Summary
Kymera Therapeutics reported financial results for Q4 and full year 2025, highlighted by a $692 million equity raise, pipeline progress including initiation of Phase 2b trials for KT-621 in atopic dermatitis and asthma, and a new Chief Development Officer appointment. The company ended 2025 with $1.6 billion in cash, providing runway into 2029.
Key Financial Metrics
Key Facts
- Collaboration revenue declined 16.7% YoY to $39.2 million in 2025
- R&D expenses increased 31.8% YoY to $316.6 million in 2025
- Net loss widened to $311.4 million in 2025 from $223.9 million in 2024
- Completed $692 million equity offering in December 2025
- Cash balance of $1.6 billion as of December 31, 2025, providing runway into 2029
- Initiated dosing in KT-579 Phase 1 trial and expanded KT-621 Phase 2b trials
Financial Impact
Revenue decreased by $7.9 million YoY while R&D spending increased by $76.4 million, resulting in a $87.5 million wider net loss. The $692 million capital raise significantly strengthened the balance sheet.
Risk Factors
- Continuing reliance on external funding as collaboration revenue declines
- High R&D spending with no near-term commercial products
- Clinical trial risks for KT-621 and KT-579 programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073386 |
| Document: kymr-20260226.htm | 0001193125-26-073386 |
| Document: 0001193125-26-073386-index-headers.html | 0001193125-26-073386 |
| Document: 0001193125-26-073386-index.html | 0001193125-26-073386 |
| Document: 0001193125-26-073386.txt | 0001193125-26-073386 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $105.48 $118.63 | ▲ +12.47% | ▲ +13.07% | $107.39 (+1.81%) |
Jul 8, 2026 12w ago | Insider Cluster | $114.16 $105.48 | ▲ +7.60% | ▲ +10.88% | $107.39 (+5.93%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jun 30, 2026 13w ago | 144 | $114.20 $105.25 | ▲ +7.84% | ▲ +5.65% | $107.39 (+5.96%) |
Jun 29, 2026 13w ago | 144 | $114.67 $110.05 | ▼ −4.03% | ▼ −3.00% | $107.39 (−6.35%) |
Jun 26, 2026 13w ago | Insider Cluster | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 13w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 14w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 24, 2026 14w ago | 144 | $116.46 $110.38 | ▼ −5.22% | ▼ −5.75% | $107.39 (−7.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access